Compare Cassava Sciences Inc (FLNA) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

HPE's stock is trading at $72.12, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.11 surpassing the $0.932 estimate. The company secured a $1.2 billion AI server order from Vultr and raised its networking outlook, fueling bullish technical signals and positive analyst sentiment.

The outlook remains optimistic due to AI-driven growth and raised revenue targets, but risks include high valuation multiples and volatile cash flows. With a consensus price target of $70.35, slightly below the current price, the stock faces potential near-term resistance despite strong fundamentals and institutional upgrades.